| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
120,614 |
104,874 |
$5.39M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
61,009 |
50,089 |
$3.44M |
| 87507 |
|
7,667 |
6,461 |
$1.12M |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
39,014 |
35,901 |
$844K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
39,334 |
36,193 |
$842K |
| 88312 |
|
31,310 |
28,423 |
$769K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
42,250 |
35,625 |
$766K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
38,074 |
34,699 |
$560K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
26,119 |
24,194 |
$533K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
2,422 |
2,294 |
$497K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
23,134 |
21,042 |
$432K |
| 87481 |
|
17,685 |
12,542 |
$357K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
11,830 |
8,998 |
$343K |
| 81513 |
|
7,432 |
6,701 |
$280K |
| 88342 |
|
7,726 |
6,745 |
$193K |
| 88313 |
|
10,143 |
8,917 |
$174K |
| 87653 |
|
7,602 |
6,859 |
$168K |
| 87511 |
|
5,586 |
5,145 |
$109K |
| 87563 |
|
7,727 |
7,046 |
$108K |
| 88112 |
|
6,539 |
5,820 |
$105K |
| 88141 |
|
6,746 |
6,119 |
$78K |
| 87640 |
|
3,684 |
3,364 |
$53K |
| 87486 |
|
2,412 |
2,279 |
$44K |
| 87581 |
|
2,410 |
2,278 |
$44K |
| 87480 |
|
4,020 |
3,640 |
$39K |
| 87510 |
|
3,966 |
3,590 |
$36K |
| 87660 |
|
3,469 |
3,129 |
$32K |
| 88341 |
|
483 |
401 |
$26K |
| 88142 |
|
1,806 |
1,628 |
$21K |
| 88120 |
|
273 |
245 |
$21K |
| 87529 |
|
1,053 |
500 |
$14K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
143 |
128 |
$13K |
| 88304 |
|
673 |
594 |
$12K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
427 |
386 |
$11K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
347 |
313 |
$11K |
| 88377 |
|
110 |
53 |
$7K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,094 |
1,020 |
$4K |
| 88184 |
|
79 |
29 |
$3K |
| 83993 |
|
590 |
461 |
$3K |
| 88185 |
|
80 |
29 |
$2K |
| 87505 |
|
120 |
105 |
$2K |
| 88302 |
|
85 |
81 |
$2K |
| 82653 |
|
332 |
261 |
$2K |
| 87641 |
|
76 |
68 |
$1K |
| 87500 |
|
76 |
68 |
$1K |
| 87625 |
|
116 |
115 |
$762.89 |
| 88307 |
|
13 |
12 |
$674.46 |
| 88189 |
|
80 |
30 |
$573.70 |
| 88300 |
|
49 |
48 |
$469.49 |
| 87338 |
|
156 |
118 |
$467.24 |
| 36415 |
Collection of venous blood by venipuncture |
1,027 |
891 |
$445.13 |
| 87324 |
|
61 |
44 |
$314.03 |
| 87088 |
|
74 |
70 |
$281.61 |
| 87186 |
|
45 |
42 |
$256.51 |
| 83631 |
|
42 |
37 |
$186.85 |
| 0753T |
|
440 |
376 |
$0.04 |
| 0756T |
|
33 |
28 |
$0.00 |